AZN•AstraZeneca and Oracle launched a global AI collaboration focused on clinical trial recruitment and patient care, with projects planned in the US, Middle East and Europe. The companies signed a non-binding term sheet, and the first program with M42 will target hypertension care and trial recruitment.
AstraZeneca and Oracle launched a global collaboration to use AI to improve clinical trial recruitment and bring evidence-driven insights into patient care. Projects will span the US, Middle East and Europe, combining AstraZeneca’s scientific expertise with Oracle’s real-world data, cloud infrastructure and AI capabilities. The first program, with M42 in Abu Dhabi, will focus on hypertension care and clinical trial recruitment. The companies signed a non-binding term sheet.
